ATE360068T1 - Bildgebende verfahren, diagnose und behandlung von krankheiten - Google Patents

Bildgebende verfahren, diagnose und behandlung von krankheiten

Info

Publication number
ATE360068T1
ATE360068T1 AT01992777T AT01992777T ATE360068T1 AT E360068 T1 ATE360068 T1 AT E360068T1 AT 01992777 T AT01992777 T AT 01992777T AT 01992777 T AT01992777 T AT 01992777T AT E360068 T1 ATE360068 T1 AT E360068T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
diseases
imaging procedures
imaging
Prior art date
Application number
AT01992777T
Other languages
English (en)
Inventor
Roy Bicknell
Lukasz Huminiecki
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE360068T1 publication Critical patent/ATE360068T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
AT01992777T 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten ATE360068T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24556600P 2000-11-06 2000-11-06
US27366201P 2001-03-07 2001-03-07

Publications (1)

Publication Number Publication Date
ATE360068T1 true ATE360068T1 (de) 2007-05-15

Family

ID=26937319

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06077262T ATE480622T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten
AT01992777T ATE360068T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06077262T ATE480622T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten

Country Status (12)

Country Link
US (5) US7498034B2 (de)
EP (2) EP1790728B1 (de)
JP (2) JP2004524821A (de)
AT (2) ATE480622T1 (de)
AU (3) AU2378402A (de)
CA (1) CA2427310C (de)
CY (2) CY1107609T1 (de)
DE (2) DE60143065D1 (de)
DK (2) DK1334194T3 (de)
ES (1) ES2296829T3 (de)
PT (2) PT1790728E (de)
WO (1) WO2002036771A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1790728E (pt) * 2000-11-06 2010-11-12 Cancer Rec Tech Ltd Imagiologia, diagnóstico e tratamento de doença
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
AU2003247828B2 (en) * 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
US7185814B2 (en) * 2002-10-16 2007-03-06 Dcard, Inc. Layer structure and method of manufacture for optical memory strip (OMS)
WO2004046191A2 (en) * 2002-11-20 2004-06-03 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
WO2007039256A2 (de) * 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
EP2104509A4 (de) * 2006-12-11 2010-03-24 Univ Utah Res Found Zusammensetzungen und verfahren zur behandlung von pathologischer angiogenese und gefässpermeabilität
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
US8399421B2 (en) * 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009046127A1 (en) * 2007-10-01 2009-04-09 Allos Therapeutics, Inc. Dt-diaphorase-active agents for treatment of pediatric tumors
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2567030T3 (es) 2009-09-03 2016-04-19 Cancer Research Technology Limited Inhibidores de CLEC14A
WO2011032088A1 (en) * 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
US20110105735A1 (en) * 2009-10-29 2011-05-05 Heather Desaire Methods of producing and purifying proteins
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
PL2841457T3 (pl) 2012-04-27 2019-09-30 Daiichi Sankyo Company, Limited Przeciwciało anty-ROBO4
WO2014072416A1 (en) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bone metastases
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
AU2018321825A1 (en) * 2017-08-19 2020-03-05 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (de) 1994-05-12 1996-12-18 Ono Pharmaceutical Co Polypeptide hergestellt in einer Endothel Zell-Linie und dafür kodierende DNS.
WO2000053756A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040002591A1 (en) 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
CA2298852A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
JP2001514024A (ja) 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO1999053051A2 (en) 1998-04-09 1999-10-21 Genset 5' ests and encoded human proteins
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
CA2383691A1 (en) * 1999-08-12 2001-02-22 Steven M. Ruben Human tumor necrosis factor receptor tr16
AU1190801A (en) 1999-09-30 2001-04-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
PT1790728E (pt) * 2000-11-06 2010-11-12 Cancer Rec Tech Ltd Imagiologia, diagnóstico e tratamento de doença
DK1572169T3 (da) * 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
WO2004046191A2 (en) 2002-11-20 2004-06-03 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis

Also Published As

Publication number Publication date
US7582440B2 (en) 2009-09-01
ES2296829T3 (es) 2008-05-01
US7740830B2 (en) 2010-06-22
US7498034B2 (en) 2009-03-03
JP5603145B2 (ja) 2014-10-08
DK1334194T3 (da) 2007-05-29
DE60127986D1 (de) 2007-05-31
WO2002036771A3 (en) 2002-09-06
EP1334194A2 (de) 2003-08-13
DK1790728T3 (da) 2010-12-06
US20040071711A1 (en) 2004-04-15
CA2427310A1 (en) 2002-05-10
WO2002036771A2 (en) 2002-05-10
EP1334194B1 (de) 2007-04-18
CY1110967T1 (el) 2015-06-11
US20080219924A1 (en) 2008-09-11
US20080145359A1 (en) 2008-06-19
ATE480622T1 (de) 2010-09-15
DE60143065D1 (de) 2010-10-21
EP1790728A2 (de) 2007-05-30
PT1790728E (pt) 2010-11-12
EP1790728A3 (de) 2007-06-13
US8216584B2 (en) 2012-07-10
JP2004524821A (ja) 2004-08-19
EP1790728B1 (de) 2010-09-08
US20070025913A1 (en) 2007-02-01
CA2427310C (en) 2013-12-17
US20090191572A1 (en) 2009-07-30
AU2007201584A1 (en) 2007-05-03
JP2010248210A (ja) 2010-11-04
AU2002223784B2 (en) 2007-01-18
CY1107609T1 (el) 2013-03-13
DE60127986T2 (de) 2008-01-17
PT1334194E (pt) 2007-07-17
AU2378402A (en) 2002-05-15
US20080274045A9 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
ATE480622T1 (de) Bildgebende verfahren, diagnose und behandlung von krankheiten
DE60139788D1 (de) Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
DE60108847D1 (de) Knollenförmige klappe und stent zur behandlung von gefässrückfluss
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
HUP0301835A2 (hu) Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60027415D1 (de) Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
DE59310320D1 (de) Neue Mittel zur Diagnose von Gefässerkrankungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE29901517U1 (de) Vorrichtung zur abtragenden Behandlung von Hornhaut, insbesondere bei der Fußpflege
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE395919T1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE414539T1 (de) Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen
DE60226864D1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334194

Country of ref document: EP